Clicky

COMPASS Pathways Plc(CMPS)

Description: COMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing.


Keywords: Health Sciences Entheogens Psychoactive Drugs Drug Discovery Mental Health Depression FDA Major Depressive Disorder Breakthrough Therapy MP3 Psilocybin Treatment Resistant Depression

Home Page: compasspathways.com

CMPS Technical Analysis

33 Broadwick Street
London, W1F 0DQ
United Kingdom
Phone: 44 64 6905 3974


Officers

Name Title
Mr. George Jay Goldsmith Exec. Chairman & Co-Founder
Dr. Ekaterina Malievskaia M.D. Co-Founder, Chief Innovation Officer & Exec. Director
Dr. Guy Goodwin Chief Medical Officer
Mr. Kabir Nath M.A., M.B.A. Chief Exec. Officer
Mr. Michael F. Falvey Chief Financial Officer
Dr. Greg Ryslik Ph.D. Exec. VP of AI, Engineering, Digital Health Research & Technology
Mr. Stephen D. Schultz Sr. VP of Investor Relations
Mr. Matthew Owens Gen. Counsel & Chief Legal Officer
Mr. Christopher Williams Chief Communications Officer
Ms. Anne Benedict Chief People Officer

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.184
Price-to-Sales TTM: 0
IPO Date: 2020-09-18
Fiscal Year End: December
Full Time Employees: 116
Back to stocks